SpringerLink
Log in

Neuroimmunology

  • Chapter
  • First Online:
Atlas of Clinical Neurology

  • 2821 Accesses

Abstract

The immune system is devoted to the defense of self, directed against non-self pathogens—parasites, fungi, viruses, and bacteria. Antigens are the distinguishing characteristics of pathogens, used by the immune system as targets for identification to attack invaders. The immune system can be divided into two functional subsystems: innate immunity and adaptive immunity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Genkins G, Kornfeld P, Papatestas AE, Bender AN, Matta RJ. Clinical experience in more than 2000 patients with myasthenia gravis. Ann N Y Acad Sci. 1987;505:500–13.

    Article  CAS  PubMed  Google Scholar 

  2. Dalakas MC. Treatment and management of autoimmune myopathies. In: Bertorini TE, editor. Neuromuscular disorders. Philadelphia: Elsevier Saunders; 2010. p. 395–408.

    Google Scholar 

  3. Tsokos GC, Goust J-M, Virella G. Pathogenic factors involved in the onset of autoimmune disease. In: Virella G, editor. Medical immunology. 5th ed. New York: CRC Press; 2001. p. 393–7.

    Google Scholar 

  4. Lechner-Scott J, Spencer B, de Malmanche T, Attia J, Fitzgerald M, Trojano M, et al. MSBase study group. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler. 2012;18:974–82.

    Article  CAS  PubMed  Google Scholar 

  5. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. TYSABRI Observational Program (TOP) Investigators. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7.

    Article  PubMed  Google Scholar 

  7. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.

    Article  CAS  PubMed  Google Scholar 

  8. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.

    Article  CAS  PubMed  Google Scholar 

  9. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.

    Article  CAS  PubMed  Google Scholar 

  10. Sharma N, Akhade A, Qadri A. Sphingosine-1-phosphate suppresses TLR-induced CXCL8 secretion from human T cells. J Leukoc Biol. 2013;93:521–8.

    Article  CAS  PubMed  Google Scholar 

  11. Sanford M. Fingolimod: a review of its use in relapsing-remitting multiple sclerosis. Drugs. 2014;74:1411–33.

    Article  CAS  PubMed  Google Scholar 

  12. Calabresi A, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56.

    Article  CAS  PubMed  Google Scholar 

  13. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. TEMSO trial group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.

    Article  PubMed  Google Scholar 

  15. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. DEFINE study investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.

    Article  CAS  PubMed  Google Scholar 

  16. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. CONFIRM study investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.

    Article  CAS  PubMed  Google Scholar 

  17. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–92.

    Article  PubMed  Google Scholar 

  18. Beck RW. Optic neuritis: clinical considerations and the relationship to multiple sclerosis. Neuro-Ophthalmology. 1998;20:1–20.3.

    Article  Google Scholar 

  19. Sorensen TL, Frederiksen JL, Bronnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology. 1999;53:473–8.

    Article  CAS  PubMed  Google Scholar 

  20. Druschky A, Heckmann JG, Claus D, Katalinic A, Druschky KF, Neundörfer B. Progression of optic neuritis to multiple sclerosis: an 8-year follow-up study. Clin Neurol Neurosurg. 1999;101:189–92.

    Article  CAS  PubMed  Google Scholar 

  21. Hecklenlively JR, Ferreyra HA. Autoimmune retinopathy: a review and summary. Semin Immunopathol. 2008;30:127–34.

    Article  Google Scholar 

  22. Luque FA, Jaffe SL. Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol. 2007;79:341–56.

    Article  CAS  PubMed  Google Scholar 

  23. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:909–14.

    Article  PubMed  Google Scholar 

  24. Polman C, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292–302.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Morrissey SP, Miller DH, Kendall BE, Kingsley DP, Kelly MA, Francis DA, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993;116:135–46.

    Article  PubMed  Google Scholar 

  26. Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol. 2015;25(S2):157–65.

    Article  PubMed  Google Scholar 

  27. Lövblad KO, Anzalone N, Dörfler A, Essig M, Hurwitz B, Kappos L, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. Am J Neuroradiol. 2010;31:983–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Swinnen C, Lunskens S, Deryck O, Casselman J, Vanopdenbosch L. MRI characteristics of trigeminal nerve involvement in patients with multiple sclerosis. Mult Scler Relat Disord. 2013;2:200–3.

    Article  PubMed  Google Scholar 

  29. Comi G, Filippi M, Martinelli V, Scotti G, Locatelli T, Medaglini S, et al. Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. Eur Neurol. 1993;33:232–7.

    Article  CAS  PubMed  Google Scholar 

  30. McDonald WI, Miller DH. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993;43:2632–7.

    Article  PubMed  Google Scholar 

  31. Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, et al. Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol. 2016;37(3):394–401.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kingsley D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 1992;42:60–3.

    Article  CAS  PubMed  Google Scholar 

  33. Offenbacher H, Fazekas F, Schmidt R, Freidl W, Flooh E, Payer F, Lechner H. Assessment of MRI criteria for a diagnosis of MS. Neurology. 1993;43:905–9.

    Article  CAS  PubMed  Google Scholar 

  34. Comi G, Filippi M, Martinelli V, Sirabian G, Visciani A, Campi A, et al. Brain magnetic resonance imaging correlates of cognitive impairment in multiple sclerosis. J Neurol Sci. 1993;115:S66–73.

    Article  PubMed  Google Scholar 

  35. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu—associated paraneoplastic encephalomyelitis/sensory neuronopathy: a clinical study of 71 patients. Medicine (Baltimore). 1992;71:59–72.

    Article  CAS  Google Scholar 

  36. Musunuru K, Kesari S. Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. J Neuro-Oncol. 2008;90:213–6.

    Article  CAS  Google Scholar 

  37. Klaas JP, Ahlskog JE, Pittock SJ, Matsumoto JY, Aksamit AJ, Bartleson JD, et al. Adult-onset opsoclonus-myoclonus syndrome. Arch Neurol. 2012;69:1598–607.

    Article  PubMed  Google Scholar 

  38. Jacobson DM, Thirkill CL, Tip** SJ. A clinical triad to diagnose paraneoplastic retinopathy. Ann Neurol. 1990;28:162–7.

    Article  CAS  PubMed  Google Scholar 

  39. Ciccoto G, Blaya M, Kelley RE. Stiff person syndrome. Neurol Clin. 2013;31:319–28.

    Article  Google Scholar 

  40. Alexopoulos H, Dalakas MC. A critical update on the immunopathogenesis of stiff person syndrome. Eur J Clin Investig. 2010;40:1018–25.

    Article  CAS  Google Scholar 

  41. Ali F, Rowley M, Jayakrishnan B, Teuber S, Gershwin ME, Mackay IR. Stiff-person syndrome (SPS) and anti-GAD-related CNS degenerations: protean additions to the autoimmune central neuropathies. J Autoimmun. 2011;37:79–87.

    Article  CAS  PubMed  Google Scholar 

  42. Bien CG, Granata T, Antozzi C, Cross JH, Dulac O, Kurthen M, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128:454–71.

    Article  CAS  PubMed  Google Scholar 

  43. Varadkar S, Bien CG, Kruse CA, Jensen FE, Bauer J, Pardo CA, et al. Rasmussen’s encephalitis: clinical features, pathobiology and treatment advances. Lancet Neurol. 2014;13(2):195–205.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Greenlee JE, Rose JW. Controversies in neurological infectious diseases. Semin Neurol. 2000;20:375–86.

    Article  CAS  PubMed  Google Scholar 

  45. Greenlees J, Brashear HR. Remote effects of carcinoma. In: Johnson RT, Griffin JW, editors. Current therapy in neurologic disease. 5th ed. St. Louis: Mosby-Year Book; 1995. p. 167–98.

    Google Scholar 

  46. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327–40.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Yuki N, Hartung H-P. Guillain–Barré syndrome. N Engl J Med. 2012;366:2294–304.

    Article  CAS  PubMed  Google Scholar 

  48. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469–82.

    Article  PubMed  CAS  Google Scholar 

  49. Latov N. Diagnosis of CIDP. Neurology. 2002;59:S2–6.

    Article  PubMed  Google Scholar 

  50. Koller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352:1342–56.

    Article  Google Scholar 

  51. Hughes RAC. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat. 2002;200:331–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med. 1986;314:461–5.

    Article  CAS  PubMed  Google Scholar 

  53. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838–45.

    Article  CAS  PubMed  Google Scholar 

  54. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. ICE Study Group. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136–44.

    Article  CAS  PubMed  Google Scholar 

  55. Krendel DA. Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol. 1995;52:1053–61.

    Article  CAS  PubMed  Google Scholar 

  56. Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. Lancet Neurol. 2014;13:67–82.

    Article  PubMed  Google Scholar 

  57. Olney RK. Neuropathies in connective tissue disease. Muscle Nerve. 1992;15:531–42.

    Article  CAS  PubMed  Google Scholar 

  58. Collins MP, Arnold WD, Kissel JT. The neuropathies of vasculitis. Neurol Clin. 2013;31:557–95.

    Article  PubMed  Google Scholar 

  59. Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain. 1996;119:1441–8.

    Article  PubMed  Google Scholar 

  60. Parry GJ. Inflammatory demyelinating polyneuropathies: new perspectives in treatment. Adv Neuroimmunol. 1994;1:9–15.

    Google Scholar 

  61. Hayes MT. Analyzing new strategies to diagnose and treat autoimmune neuropathies. Adv Neuroimmunol. 1995;2:10–7.

    Google Scholar 

  62. Parry G, Swenson MR. When is antibody testing useful and what therapy is effective in immune-mediated neuropathies? Adv Neuroimmunol. 1995;2:18–22.

    Google Scholar 

  63. Sederholm BH. Treatment of acute immune-mediated neuropathies: Guillain-Barré syndrome and clinical variants. Semin Neurol. 2010;30:365–72.

    Article  PubMed  Google Scholar 

  64. Sinha S, Newsom-Davis J, Mills K, Byrne N, Lang B, Vincent A. Autoimmune aetiology for acquired neuromyotonia (Isaacs’ syndrome). Lancet. 1991;338:75–7.

    Article  CAS  PubMed  Google Scholar 

  65. Maddison P. Neuromyotonia. Clin Neurophysiol. 2006;117:2118–27.

    Article  PubMed  Google Scholar 

  66. Newsom-Davis J, Mills KR. Immunological associations of acquired neuromyotonia (Isaacs’ syndrome): report of five cases and literature review. Brain. 1993;116:453–69.

    Article  PubMed  Google Scholar 

  67. Quarles RH, Colman DR, Salzer JL, Trapp BD. Myelin-associated glycoprotein: structure-function relationships and involvement in neurological diseases. In: Martenson RE, editor. Myelin: biology and chemistry. Boca Raton: CRC Press; 1992. p. 413–48.

    Google Scholar 

  68. Dalakas MC. Pathogenesis of immune-mediated neuropathies. Biochim Biophys Acta. 2015;1852(4):658–66.

    Article  CAS  PubMed  Google Scholar 

  69. Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375:2750–81.

    Article  CAS  Google Scholar 

  70. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve. 2004;29:484–505.

    Article  PubMed  Google Scholar 

  71. Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol. 2004;24:41–8.

    Article  PubMed  Google Scholar 

  72. Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis. 2011;2011:1–6.

    Google Scholar 

  73. Soliven BC, Lange DJ, Penn AS, Younger D, Jaretzki A 3rd, Lovelace RE, Rowland LP. Seronegative myasthenia gravis. Neurology. 1988;38:514–7.

    Article  CAS  PubMed  Google Scholar 

  74. Newsom-Davis J. Myasthenia gravis: the Lambert-Eaton myasthenic syndrome and acquired myotonia. In Diagnostic and Therapeutic Approaches to Myasthenia Gravis. In: Proceedings of the Annual Meeting of the Myasthenia Gravis Foundation of America, Salt Lake City, Utah, April 28, 1995.

    Google Scholar 

  75. Lindstrom JM. Pathophysiology of myasthenia gravis: the mechanisms behind the disease. Adv Neuroimmunol. 1994;1:3–8.

    Google Scholar 

  76. Section II: Illustrations of selected waveforms. Muscle Nerve. 1987;10:G24–G52.

    Google Scholar 

  77. Mendell J. Neuromuscular junction disorders: a guide to diagnosis and treatment. Adv Neuroimmunol. 1994;1:9–16.

    Google Scholar 

  78. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol. 2004;24:149–53.

    Article  PubMed  Google Scholar 

  79. Titulaer MJ, Lang B, Verschuuren JGM. Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10:1098–107.

    Article  PubMed  Google Scholar 

  80. Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Hohlfeld R, Engel AG, Ii K, Harper MC. Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. N Engl J Med. 1991;324:877–81.

    Article  CAS  PubMed  Google Scholar 

  82. Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45:1302–4.

    Article  CAS  PubMed  Google Scholar 

  83. Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol. 2012;25(5):630–9.

    Article  PubMed  Google Scholar 

  84. Engel WK, Askanas V. Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology. 2006;66:S20–9.

    Article  PubMed  Google Scholar 

  85. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;327:1734–47.

    Article  Google Scholar 

  86. Cover photo from Adv Neuroimmunol. 1995;2(1).

    Google Scholar 

  87. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today. 1994;15:269–74.

    Article  CAS  PubMed  Google Scholar 

  88. Hohlfeld R. New concepts in the immunobiology of inflammatory myopathy. Adv Neuroimmunol. 1995;2:4–8.

    Google Scholar 

  89. Griggs RC, Mendell JR, Miller RG. Inflammatory myopathy. In: Evaluation and treatment of myopathies. Philadelphia: FA Davis; 1995. p. 172.

    Google Scholar 

  90. Choy EHS, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology. 2002;41(1):7–13.

    Article  CAS  PubMed  Google Scholar 

  91. Shaibani A, Harati Y. Idiopathic inflammatory myopathies: polymyositis, dermatomyositis, inclusion body myositis. In: Rolak LA, Harati Y, editors. Neuro-immunology for the clinician. Boston: Butterworth-Heinemann; 1997. p. 301–16.

    Google Scholar 

  92. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology. 2006;66(2):S33–8.

    Article  CAS  PubMed  Google Scholar 

  93. Mendell JR, Sahenk Z, Gales T, Paul L. Amyloid filaments in inclusion body myositis: novel findings provide insight into nature of filaments. Arch Neurol. 1991;48:1229–34.

    Article  CAS  PubMed  Google Scholar 

  94. Griggs RC. The current status of treatment for inclusion-body myositis. Neurology. 2006;66:S30–2.

    Article  PubMed  Google Scholar 

  95. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love M, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132:1536–44.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83:2239–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lander Medical Clinic, Lander, WY, USA

    Michael R. Swenson

Authors
  1. Michael R. Swenson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael R. Swenson .

Editor information

Editors and Affiliations

  1. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Roger N. Rosenberg

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Swenson, M.R. (2019). Neuroimmunology. In: Rosenberg, R. (eds) Atlas of Clinical Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-03283-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-03283-8_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-03281-4

  • Online ISBN: 978-3-030-03283-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation